Cargando…

Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation

BACKGROUND: Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transpla...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomura, Shosaku, Maeda, Yoshinobu, Ishii, Kazuyoshi, Katayama, Yuta, Yagi, Hideo, Fujishima, Naoto, Ota, Shuichi, Moriyama, Masato, Ikezoe, Takayuki, Miyazaki, Yasuhiko, Hayashi, Kunio, Fujita, Shinya, Satake, Atsushi, Ito, Tomoki, Kyo, Taiichi, Tanimoto, Mitsune
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723029/
https://www.ncbi.nlm.nih.gov/pubmed/26848281
http://dx.doi.org/10.2147/JBM.S93008
Descripción
Sumario:BACKGROUND: Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transplantation (aHSCT). However, changes to circulating levels of HMGB1 after aHSCT are poorly understood. MATERIALS AND METHODS: The study cohort included 289 patients who underwent aHSCT at one of 25 institutions in Japan. We have investigated the relationship between HMGB1 and PAI-1 following aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment. Additionally, levels of HMGB1 at day 0 were significantly increased in TBI+ patients and cyclophosphamide/TBI patients. CONCLUSION: Our data revealed that an increased level of HMGB1 at day 0 following aHSCT correlates with increased PAI-1 after aHSCT, which is consistent with previous reports. Increased HMGB1 at day 0 after a conditioning regimen may play a role in transplantation-associated coagulopathy following aHSCT, because PAI-1 can accelerate procoagulant activity.